Versant Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

Versant Capital Management’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.8K	Sell	720 -53	-7%	-$481	﹤0.01%	2313
2026 Q1	$9.79K	Buy	773 +53	+7%	+$602	﹤0.01%	2147
2025 Q4	$5.89K	Hold	720	–	–	﹤0.01%	2193
2025 Q3	$8.64K	Hold	720	–	–	﹤0.01%	1994
2025 Q2	$7.31K	Buy	+720	New	+$4.83K	﹤0.01%	2030
2025 Q1	–	Sell	-478	Closed	-$3.86K	–	2600
2024 Q4	$3.86K	Buy	+478	New	+$4.39K	﹤0.01%	1878

Other funds holding ORIC

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Versant Capital Management's ORIC Position: Q2 2026 in Review

Versant Capital Management reduced its Oric Pharmaceuticals (ORIC) stake by 6.9% in Q2 2026, selling an estimated $481 and leaving 720 shares worth $7.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2313.

Versant Capital Management first reported a position in ORIC in Q4 2024 and has held it in 6 quarters since. The position peaked at $9.79K in Q1 2026. 6 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

Versant Capital Management held 720 shares of Oric Pharmaceuticals worth $7.8K as of Q2 2026.
Versant Capital Management sold 53 Oric Pharmaceuticals shares in Q2 2026, an estimated $481.
Oric Pharmaceuticals made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2313 holding.
Versant Capital Management first reported a position in Oric Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
Versant Capital Management's Oric Pharmaceuticals position peaked at $9.79K in Q1 2026.
6 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.